Onconetix, Inc. Other Cost of Operating Revenue
Onconetix, Inc. (ONCO) reported Other Cost of Operating Revenue of $171.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherCostOfOperatingRevenue · last filed 2024-05-20
- Onconetix, Inc. other cost of operating revenue for the quarter ending 2024-03-31 was $171.00K.
- Onconetix, Inc. other cost of operating revenue for fiscal 2023 was $31.00K.
| Period end | Other Cost of Operating Revenue 3 month | Other Cost of Operating Revenue 12 month |
|---|---|---|
| 2024-03-31 | $171.00K 10-Q · filed 2024-05-20 | |
| 2023-12-31 | $31.00K 10-K · filed 2024-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |